# TRANSGENIC MOUSE MODEL ALZHEIMER'S DISEASE AMYLOIDOSIS

> **NIH NIH R01** · CALIFORNIA BIOTECHNOLOGY, INC. · 1991 · $117,915

## Abstract

The goal of this research program is to determine the role of amyloid
plaque formation in the etiology of Alzheimer's disease.  To be able to
study the underlying mechanism(s) and to examine the consequences of beta-
amyloid deposition, we are developing a small animal model of this
pathological event.  Transgenic mice have been generated which display
extracellular beta-amyloid immunoreactive deposits in their brains.  These
deposits morphologically resemble several beta-amyloid immunoreactive
structures observed in the brains of Alzheimer's disease victims.  One
research objective is to further characterize these transgenic mice as to
similarity of their histopathology to the human condition.  Possible age-
dependent occurrence of beta-amyloid deposits, cytoskeletal alterations,
abnormalities of neurotransmitter systems, and neuronal cell loss will be
investigated using immunocytochemistry.  Another objective of the research
is to determine the mechanism of beta-amyloid formation by producing new
transgenic mice.  These new transgenic mice will be programmed to express
exogenous beta-amyloid precursor genes similar to those used to produce the
phenotype of beta-amyloid formation - except for specific coding sequence
alterations.  The mice expressing the mutated beta-amyloid precursor genes
will be evaluated for beta-amyloid deposits again using
immunocytochemistry.  The resulting phenotypes of the new transgenic mice
should further define the specific domains of the beta-amyloid precursor
which are involved in amyloid formation.  Both the development of a mouse
model of Alzheimer's disease amyloidosis and the elucidation of the
mechanism of amyloid formation may be useful in the identification of novel
therapeutic agents designed to prevent beta-amyloid formation in
individuals with this disease.

## Key facts

- **NIH application ID:** 3122583
- **Project number:** 1R01AG010665-01
- **Recipient organization:** CALIFORNIA BIOTECHNOLOGY, INC.
- **Principal Investigator:** BARBARA L CORDELL
- **Activity code:** R01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 1991
- **Award amount:** $117,915
- **Award type:** 1
- **Project period:** 1991-09-29 → 1994-06-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/3122583

## Citation

> US National Institutes of Health, RePORTER application 3122583, TRANSGENIC MOUSE MODEL ALZHEIMER'S DISEASE AMYLOIDOSIS (1R01AG010665-01). Retrieved via MORVS 2026-10-25 from https://api.morvs.ai/grant/nih/3122583. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*